Pyxis Oncology (NASDAQ:PYXS) Coverage Initiated by Analysts at Stifel Nicolaus

Equities research analysts at Stifel Nicolaus assumed coverage on shares of Pyxis Oncology (NASDAQ:PYXS) in a research report issued to clients and investors on Monday. The brokerage set a “buy” rating and a $9.00 price target on the stock. Stifel Nicolaus’ price objective would suggest a potential upside of 126.47% from the company’s previous close.

A number of other research firms have also recently issued reports on PYXS. Weiss Ratings restated a “sell (d-)” rating on shares of Pyxis Oncology in a report on Wednesday, October 8th. Wall Street Zen downgraded shares of Pyxis Oncology from a “hold” rating to a “sell” rating in a research note on Friday, October 3rd. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of Pyxis Oncology in a research report on Tuesday, August 19th. Zacks Research upgraded shares of Pyxis Oncology from a “hold” rating to a “strong-buy” rating in a research note on Monday, October 13th. Finally, Guggenheim assumed coverage on shares of Pyxis Oncology in a research note on Wednesday, September 3rd. They set a “buy” rating and a $5.00 price target for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Pyxis Oncology presently has an average rating of “Moderate Buy” and an average price target of $8.00.

Pyxis Oncology Trading Up 11.6%

PYXS traded up $0.41 during trading hours on Monday, hitting $3.97. The company’s stock had a trading volume of 1,215,319 shares, compared to its average volume of 608,932. The stock has a market cap of $246.47 million, a price-to-earnings ratio of -2.46 and a beta of 1.40. The business’s 50-day moving average price is $2.47 and its 200-day moving average price is $1.62. Pyxis Oncology has a 12 month low of $0.83 and a 12 month high of $5.39.

Pyxis Oncology (NASDAQ:PYXS) last released its quarterly earnings results on Monday, November 3rd. The company reported ($0.35) EPS for the quarter, topping the consensus estimate of ($0.36) by $0.01. On average, analysts forecast that Pyxis Oncology will post -1.04 earnings per share for the current year.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently added to or reduced their stakes in the company. Catalyst Funds Management Pty Ltd purchased a new stake in shares of Pyxis Oncology during the second quarter valued at about $26,000. Kingstone Capital Partners Texas LLC acquired a new position in shares of Pyxis Oncology during the second quarter worth $37,000. XTX Topco Ltd purchased a new stake in shares of Pyxis Oncology during the 2nd quarter valued at $40,000. Velan Capital Investment Management LP acquired a new stake in shares of Pyxis Oncology in the 2nd quarter worth $44,000. Finally, Acadian Asset Management LLC purchased a new position in Pyxis Oncology during the 1st quarter worth $81,000. 39.09% of the stock is currently owned by institutional investors.

About Pyxis Oncology

Pyxis Oncology, Inc, a clinical stage company, engages in the development of therapeutics to treat cancers. Its lead antibody-drug conjugates (ADC) product candidate is PYX-201, an investigational novel ADC consisting of human immunoglobulin G1 (IgG1), which is in Phase 1 clinical trial to treat patients with relapsed or refractory solid tumors; and lead immuno-oncology (IO) product candidate is PYX-106, an investigational fully human IgG1 Siglec-15-targeting antibody that is in Phase 1 clinical trial to treat patients with advanced solid tumors.